The clinical event is real and documented on the sponsors' official channels. Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (V940 or mRNA-4157), an mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma . The release states this represents the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone .

The patient number checks out. INTerpath-001 is a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial (NCT05933577); it enrolled 1,137 patients who, following complete surgical resection, were randomized 2:1 to intismeran plus KEYTRUDA versus KEYTRUDA alone . Enrollment was restricted to patients with surgically resected stage IIB, IIC, III or IV cutaneous melanoma who were disease free and had received no prior systemic therapy, with ocular and mucosal melanoma excluded .

Critically, this is an interim readout with no effect size published. At a pre-specified interim analysis, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival, the primary endpoint, and distant metastasis-free survival, a key secondary endpoint; no specific hazard ratios or p-values were disclosed in the topline announcement, and full data are expected at an upcoming international medical meeting . The companies did not release the size of the benefit, no hazard ratio or absolute difference was disclosed, and the data have not been presented at a medical meeting or published . Overall survival data remain immature.

On the AI element, the strongest source is Moderna's own description of its pipeline, published well before this readout. Moderna states that on the design end, a series of fully integrated AI algorithms takes next-generation sequencing data from tumor and blood samples, reviews their genetic mutations, and predicts up to 34 of those neoantigens that are most likely to elicit an immune response, and that the algorithm has the potential to learn over time. This was echoed by a named Moderna executive in trade press: the algorithm reviews the genetic mutations present in a patient's tumor and predicts up to 34 neoantigens most likely to elicit an immune response, according to Kyle Holen, head of development, therapeutics and oncology at Moderna . Independent-of-Moderna framing of the same point appeared in coverage of the readout, including a clinician explanation that artificial intelligence is then used to help scientists figure out which of the hundreds of mutations should be included in the vaccine , and a company representative's remark that these tasks historically took a lot of time and it would not be feasible to do this for every individual patient without the power of AI .

The attribution to Moderna alone is contested by at least one outlet that corrected itself on exactly this point. C&EN updated its article on Aug 19 2026 to correctly identify the developer, noting the vaccine is being jointly developed by Merck & Co. and Moderna, not solely by Moderna.

The cited source, Reuters, exists and reported the result. The Reuters story by Michael Erman and Julie Steenhuysen reported that Moderna and Merck said a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, that the trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed, and that no new safety signals emerged . The AI framing is not visible in the portions of the Reuters copy retrieved.